inclusion criteria: * tested pcr positive for sars-cov-2by nasopharyngeal swab, oropharyngeal swab, or saliva. * mild covid-19, defined as who ordinal scale \<4 . * respiratory rate \< 20 bpm, hr \< 90 bpm, and spo2 \> 93% on room air at sea level. * absolute lymphocyte count (alc) \< 1500 cells/mm3 at the time of screening. * ast/alt ≤ 3.0 x uln, total bilirubin ≤ 1.5 x uln (except if due to gilbert's syndrome). -≥ 18 years of age. * first day of treatment must be no more than 10 days from onset of covid-19 symptoms. * must be willing to be closely monitored in the hospital or in an alternate setting (e.g. clinical trial unit) for at least the first 7 days (±2 days allowed) following nt-i7/placebo injection. * individuals of reproductive potential must agree to either abstinence or use of at least one study-approved form of contraception when engaging in sexual activities that can result in pregnancy from the time of screening through 60 days for female and 120 days for male after study agent administration. acceptable forms of contraception for this study are male or female condoms, diaphragms or cervical caps with a spermicide, or non-hormonal intrauterine devices. * patients with factors or concomitant illness associated with higher risk of mortality due to covid-19 (such as older age, hypertension, diabetes, and/or copd) are eligible. * able to understand and willing to sign an irb approved written informed consent document.

inclusion criteria: * tested pcr positive for sars-cov-2by nasopharyngeal swab, oropharyngeal swab, or saliva. * mild covid-19, defined as who ordinal scale \<4 . * respiratory rate \< 20 bpm, hr \< 90 bpm, and spo2 \> 93% on room air at sea level. * absolute lymphocyte count (alc) \< 1500 cells/mm3 at the time of screening. * ast/alt ≤ 3.0 x uln, total bilirubin ≤ 1.5 x uln (except if due to gilbert's syndrome). -≥ 18 years of age. * first day of treatment must be no more than 10 days from onset of covid-19 symptoms. * must be willing to be closely monitored in the hospital or in an alternate setting (e.g. clinical trial unit) for at least the first 7 days (±2 days allowed) following nt-i7/placebo injection. * individuals of reproductive potential must agree to either abstinence or use of at least one study-approved form of contraception when engaging in sexual activities that can result in pregnancy from the time of screening through 60 days for female and 120 days for male after study agent administration. acceptable forms of contraception for this study are male or female condoms, diaphragms or cervical caps with a spermicide, or non-hormonal intrauterine devices. * patients with factors or concomitant illness associated with higher risk of mortality due to covid-19 (such as older age, hypertension, diabetes, and/or copd) are eligible. * able to understand and willing to sign an irb approved written informed consent document.

inclusion criteria: - tested pcr positive for sars-cov-2by nasopharyngeal swab, oropharyngeal swab, or saliva. - mild covid-19, defined as who ordinal scale <4 . - respiratory rate < 20 bpm, hr < 90 bpm, and spo2 > 93% on room air at sea level. - absolute lymphocyte count (alc) < 1500 cells/mm3 at the time of screening. - ast/alt ≤ 3.0 x uln, total bilirubin ≤ 1.5 x uln (except if due to gilbert's syndrome). -≥ 18 years of age. - first day of treatment must be no more than 10 days from onset of covid-19 symptoms. - must be willing to be closely monitored in the hospital or in an alternate setting (e.g. clinical trial unit) for at least the first 7 days (±2 days allowed) following nt-i7/placebo injection. - individuals of reproductive potential must agree to either abstinence or use of at least one study-approved form of contraception when engaging in sexual activities that can result in pregnancy from the time of screening through 60 days for female and 120 days for male after study agent administration. acceptable forms of contraception for this study are male or female condoms, diaphragms or cervical caps with a spermicide, or non-hormonal intrauterine devices. - patients with factors or concomitant illness associated with higher risk of mortality due to covid-19 (such as older age, hypertension, diabetes, and/or copd) are eligible. - able to understand and willing to sign an irb approved written informed consent document.

inclusion criteria: - tested pcr positive for sars-cov-2by nasopharyngeal swab, oropharyngeal swab, or saliva. - mild covid-19, defined as who ordinal scale <4 . - respiratory rate < 20 bpm, hr < 90 bpm, and spo2 > 93% on room air at sea level. - absolute lymphocyte count (alc) < 1500 cells/mm3 at the time of screening. - ast/alt ≤ 3.0 x uln, total bilirubin ≤ 1.5 x uln (except if due to gilbert's syndrome). -≥ 18 years of age. - first day of treatment must be no more than 10 days from onset of covid-19 symptoms. - must be willing to be closely monitored in the hospital or in an alternate setting (e.g. clinical trial unit) for at least the first 7 days (±2 days allowed) following nt-i7/placebo injection. - individuals of reproductive potential must agree to either abstinence or use of at least one study-approved form of contraception when engaging in sexual activities that can result in pregnancy from the time of screening through 60 days for female and 120 days for male after study agent administration. acceptable forms of contraception for this study are male or female condoms, diaphragms or cervical caps with a spermicide, or non-hormonal intrauterine devices. - patients with factors or concomitant illness associated with higher risk of mortality due to covid-19 (such as older age, hypertension, diabetes, and/or copd) are eligible. - able to understand and willing to sign an irb approved written informed consent document.